Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35960908

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Jan 20
First author
Dimopoulos MA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Mar 20;41(9):1788. doi: 10.1200/JCO.22.02098.
    note
    Source null
    related pmid
    36626704
    relationship
    Comment in

Authors and identifiers

  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Dytfeld D
    type
    Author
  3. name
    Grosicki S
    type
    Author
  4. name
    Moreau P
    type
    Author
  5. name
    Takezako N
    type
    Author
  6. name
    Hori M
    type
    Author
  7. name
    Leleu X
    type
    Author
  8. name
    LeBlanc R
    type
    Author
  9. name
    Suzuki K
    type
    Author
  10. name
    Raab MS
    type
    Author
  11. name
    Richardson PG
    type
    Author
  12. name
    Popa McKiver M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Dytfeld D
    type
    Author
  3. name
    Grosicki S
    type
    Author
  4. name
    Moreau P
    type
    Author
  5. name
    Takezako N
    type
    Author
  6. name
    Hori M
    type
    Author
  7. name
    Leleu X
    type
    Author
  8. name
    LeBlanc R
    type
    Author
  9. name
    Suzuki K
    type
    Author
  10. name
    Raab MS
    type
    Author
  11. name
    Richardson PG
    type
    Author
  12. name
    Popa McKiver M
    type
    Author
bibliography ids
  1. nci-bib-2b65338d4089fa35ffda91c1
book metadata
content sha256
0a6806315c31777153e02c0ccf05cf0722b5ac32b1fa9b3dd98bb7090ff79463
document type
citation
dois
  1. 10.1200/JCO.21.02815
electronic publication date
display
2022 Aug 12
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35960908
immutable id
pubmed:35960908@0a6806315c31777153e02c0ccf05cf0722b5ac32b1fa9b3dd98bb7090ff79463
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
3
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
568-578
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Mar 20;41(9):1788. doi: 10.1200/JCO.22.02098.
    note
    Source null
    related pmid
    36626704
    relationship
    Comment in
outcomes validated
false
pmid
35960908
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
7e26ed36ee255a88818814756eb5b9e756f3036dcdd14cef71b70a9adc64b937
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2023 Jan 20
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35960908/
title
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Preserved source evidence · Not medical advice